The company's recent experience demonstrates the impasse between genetic test developers and payors about the types of clinical evidence needed for coverage.
The Netherlands is considering whether and how to implement NIPT and researchers have applied for a license to study NIPT in average risk pregnancies.
The company was unable to comply with requirements including having a minimum bid price of at least $1 per share and stockholder equity of at least $2.5 million.
Operating since the beginning of the year in a pilot mode, the company officially launched its comprehensive PGx testing service last week.
Going forward, Complete Genomics will focus on clinical research and support BGI's noninvasive prenatal testing business as well as the launch of its benchtop sequencer in China.
In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.
A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.
Researchers report in Nature this week that farming led to genomic adaptations in humans.
The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.